The present disclosure relates to a capped dual-headed organoaluminum composition having the formula (I) and processes to prepare the same. In at least one aspect, the capped dual-headed organoaluminum compositions can be used in olefin polymerization.

The present disclosure relates to a capped dual-headed organoaluminum composition having the formula (I) and processes to prepare the same. In at least one aspect, the capped dual-headed organoaluminum compositions can be used in olefin polymerization.

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

Process for obtaining polyethylene with an MFI (190° C./2.16 kg) of at least 4 g/10 minutes and a melt strength (190° C.) of at least 8.0 cN, said process involving extrusion of low density polyethylene (LDPE) with an MFI of at least 5 g/10 minutes and a vinyl content of less than 0.25 terminal vinyl groups per 1000 C-atoms (measured with NMR in deuterated tetrachloroethane solution)—in the presence of 500-5,000 ppm, based on the weight of low density polyethylene, of an organic peroxide.

Process for obtaining polyethylene with an MFI (190° C./2.16 kg) of at least 4 g/10 minutes and a melt strength (190° C.) of at least 8.0 cN, said process involving extrusion of low density polyethylene (LDPE) with an MFI of at least 5 g/10 minutes and a vinyl content of less than 0.25 terminal vinyl groups per 1000 C-atoms (measured with NMR in deuterated tetrachloroethane solution)—in the presence of 500-5,000 ppm, based on the weight of low density polyethylene, of an organic peroxide.

A polymeric composition may include a thermoplastic polymer including: at least one monomer selected from the group consisting of vinyl esters, C2-C12 olefins, and combinations thereof; and a dynamic crosslinking group; and a dynamic crosslinking system to dynamically crosslink the thermoplastic polymer.

A polymeric composition may include a thermoplastic polymer including: at least one monomer selected from the group consisting of vinyl esters, C2-C12 olefins, and combinations thereof; and a dynamic crosslinking group; and a dynamic crosslinking system to dynamically crosslink the thermoplastic polymer.

Provided are a binder for a secondary battery, a negative electrode including the same, and a secondary battery including the same. More particularly, the binder for a secondary battery prepared by reacting a copolymer including specific repeating units and a crosslinking agent including two or more aldehyde groups has excellent mechanical properties and effectively improves a binding force. The negative electrode and the secondary battery including the binder for a secondary battery effectively suppress expansion of a negative electrode to manufacture a secondary battery having excellent charge/discharge cycle characteristics and battery performance.